[go: up one dir, main page]

FR3091177B1 - Nanoparticules et procédé de préparation - Google Patents

Nanoparticules et procédé de préparation

Info

Publication number
FR3091177B1
FR3091177B1 FR1900008A FR1900008A FR3091177B1 FR 3091177 B1 FR3091177 B1 FR 3091177B1 FR 1900008 A FR1900008 A FR 1900008A FR 1900008 A FR1900008 A FR 1900008A FR 3091177 B1 FR3091177 B1 FR 3091177B1
Authority
FR
France
Prior art keywords
nanoparticles
preparation process
preparation
cooh
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1900008A
Other languages
English (en)
Other versions
FR3091177A1 (fr
Inventor
Leza Daniela Edith Salado
Hynd Remita
Erika Porcel
Sandrine Lacombe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Paris Saclay
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paris Sud filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1900008A priority Critical patent/FR3091177B1/fr
Priority to US17/420,507 priority patent/US20220079983A1/en
Priority to EP20700015.9A priority patent/EP3906021A1/fr
Priority to PCT/EP2020/050045 priority patent/WO2020141202A1/fr
Publication of FR3091177A1 publication Critical patent/FR3091177A1/fr
Application granted granted Critical
Publication of FR3091177B1 publication Critical patent/FR3091177B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
  • Powder Metallurgy (AREA)

Abstract

Nanoparticules et procédé de préparation La présente invention concerne des nanoparticules de métal choisi parmi platine, or ou bismuth, fonctionnalisées à leur surface par du polyéthylène glycol fonctionnalisé notamment comprenant au moins une fonction OH, COOH, NH2 ou SH, et leur procédé de préparation comprenant les étapes suivantes :a) Mélanger un précurseur de nanoparticules avec un polyéthylène glycol fonctionnalisé notamment comprenant au moins une fonction OH, COOH, NH2 ou SH dans de l’eau ;b) Exposer le mélange au rayonnement ionisant. Figure pour l'abrégé : néant
FR1900008A 2019-01-02 2019-01-02 Nanoparticules et procédé de préparation Active FR3091177B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1900008A FR3091177B1 (fr) 2019-01-02 2019-01-02 Nanoparticules et procédé de préparation
US17/420,507 US20220079983A1 (en) 2019-01-02 2020-01-02 Nanoparticles and preparation method
EP20700015.9A EP3906021A1 (fr) 2019-01-02 2020-01-02 Nanoparticules et procédé de préparation
PCT/EP2020/050045 WO2020141202A1 (fr) 2019-01-02 2020-01-02 Nanoparticules et procédé de préparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1900008A FR3091177B1 (fr) 2019-01-02 2019-01-02 Nanoparticules et procédé de préparation

Publications (2)

Publication Number Publication Date
FR3091177A1 FR3091177A1 (fr) 2020-07-03
FR3091177B1 true FR3091177B1 (fr) 2025-08-29

Family

ID=67660164

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1900008A Active FR3091177B1 (fr) 2019-01-02 2019-01-02 Nanoparticules et procédé de préparation

Country Status (4)

Country Link
US (1) US20220079983A1 (fr)
EP (1) EP3906021A1 (fr)
FR (1) FR3091177B1 (fr)
WO (1) WO2020141202A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115137824B (zh) * 2022-07-01 2023-06-30 哈尔滨工程大学 一种具有热效应的硅担载双金属材料的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006244A2 (fr) * 1998-07-30 2000-02-10 Hainfeld James F Particules metalliques de chargement dans des vesicules membranaires cellulaires et particule metallique utilisee pour l'imagerie et la therapie
WO2015047787A1 (fr) * 2013-09-30 2015-04-02 Board Of Regents, The University Of Texas System Compositions nanoparticulaires pégylées
GB201704952D0 (en) * 2017-03-28 2017-05-10 Queen's Univ Of Belfast A method for the surface-modification of metal nanoparticles and uses thereof

Also Published As

Publication number Publication date
FR3091177A1 (fr) 2020-07-03
US20220079983A1 (en) 2022-03-17
WO2020141202A1 (fr) 2020-07-09
EP3906021A1 (fr) 2021-11-10

Similar Documents

Publication Publication Date Title
FR3091177B1 (fr) Nanoparticules et procédé de préparation
WO2002086443A8 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
WO2005025516A3 (fr) Anticorps monoclonaux specifiques a des intermediaires d'agregation de poids moleculaire eleve communs a des amyloides formes a partir de proteines de sequence differente
FR2373500A1 (fr) Matieres composites a base de carbure fritte pour operations de terrassement et de mine, et leur procede de preparation
JP2021505540A5 (fr)
FR2400541A1 (fr) Procede de preparation de compositions de pigments ameliorees et les compositions ainsi preparees
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
TNSN98227A1 (fr) Association pharmaceutique pour le traitement d'un dysfonctionnement sexuel et compositions la contenant.
MA44950B1 (fr) Composition , notamment composition pharmaceutique préventive et curative , a base de peroxometallate
EP1055584A3 (fr) Palier pivotant
FR3076745B1 (fr) Nanoparticules utiles comme catalyseurs d'hydrosilylation et de silylation deshydrogenante
MA55429B1 (fr) Phosphate de calcium amorphe stabilisé dopé par des ions fluorure et procédé permettant de le produire
Aaseth et al. Treatment of mercuric chloride poisoning with dimercaptosuccinic acid and diuretics: preliminary studies
HRP20231469T1 (hr) Poboljšani protokol za liječenje lupus nefritisa
CA2154428A1 (fr) Alliages a base de ti, ru, fe et o et usage de ceux-ci pour la fabrication de cathodes pour la synthese electrochimique du chlorate de sodium
CN1222381C (zh) 具有高表面均匀度的铝合金带及其制造方法
Hjortsrø et al. Does N-acetylcysteine increase the excretion of trace metals (calcium, magnesium, iron, zinc and copper) when given orally?
Mohamed et al. Multifunctional efficacy of the fabricated chitosan-coated silver nanoparticles as an antiviral agent against SARS-CoV-2: Potent and safe mechanistic insights
FR2395335A1 (fr) Procede et composition d'electrodeposition d'alliages de fer avec du nickel et/ou du cobalt
US6472381B1 (en) Method of treating psoriasis
RU2373290C2 (ru) Модифицирующая смесь
CA2394241A1 (fr) Procede d'additivation minimisant la segregation des additifs et leur migration
MA62924A1 (fr) Traitement de néoplasies malignes à l'aide d'une combinaison d'anticorps anti-pd-1
FR3098134B1 (fr) Procédé de purification de nanofils métalliques
FR2384031A1 (fr) Procede de protection de metaux corrodables et objets obtenus

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200703

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

TQ Partial transmission of property

Owner name: UNIVERSITE PARIS-SACLAY, FR

Effective date: 20221206

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FR

Effective date: 20221206

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7